Porous microneedle patch with sustained delivery of extracellular vesicles mitigates severe spinal cord injury

Ao Fang, Yifan Wang, Naiyu Guan, Yanming Zuo, Lingmin Lin, Binjie Guo, Aisheng Mo, Yile Wu, Xurong Lin, Wanxiong Cai, Xiangfeng Chen, Jingjia Ye, Zeinab Abdelrahman, Xiaodan Li, Hanyu Zheng, Zhonghan Wu, Shuang Jin, Kan Xu, Yan Huang, Xiaosong Gu, Bin Yu, Xuhua WangNature Communications 2023 · DOI

TL;DR

Researchers have developed a novel porous microneedle patch that delivers extracellular vesicles (EVs) from mesenchymal stem cells (MSCs) directly to spinal cord injury (SCI) sites. This sustained delivery system significantly reduces inflammation, promotes tissue repair, and leads to substantial functional recovery in animal models, offering a promising new therapeutic strategy for SCI.

What Problem Does This Paper Address?

Spinal cord injury (SCI) is a devastating condition with limited effective treatments. While mesenchymal stem cell (MSC)-derived secretomes, particularly extracellular vesicles (EVs), show promise in reducing SCI-induced neuroinflammation and promoting repair, efficiently delivering these EVs to the injured site without causing further damage has been a major hurdle. Traditional methods like systemic injection lead to low concentrations at the injury site, and direct transplantation can cause additional tissue damage and the EVs may not persist long enough to exert their full therapeutic effect. This paper addresses the critical need for a minimally invasive, localized, and sustained delivery system for MSC-EVs to treat SCI.

Methods

The core innovation presented is a porous microneedle (MN) patch designed for localized delivery. The MNs are fabricated from a porous gelatin methacryloyl (GelMA) hydrogel, which offers good biocompatibility and mechanical properties similar to soft spinal tissues. This porous structure is key to facilitating the sustained release of MSC-EVs.

The researchers developed two main patch types:

  • MN-MSC patch: Contains live MSCs embedded within the porous GelMA hydrogel. These MSCs continuously produce and release EVs.
  • MN-EV patch: Contains pre-isolated MSC-EVs embedded within the porous GelMA hydrogel. This serves as a direct EV delivery control.

The fabrication process involves micromolding of GelMA, crosslinking with blue light, and then embedding either MSCs or EVs. The porous nature of the GelMA was specifically engineered to enhance EV release compared to traditional GelMA.

In vivo studies involved inducing a contusive SCI model in rats. The MN-MSC or MN-EV patches were then implanted directly onto the injured spinal cord site, beneath the dura mater. Various analyses were performed, including:

  • Histology and Immunohistochemistry: To assess tissue damage, inflammation (Iba1, TNF-α, IL-1β), neuroprotection (GFAP, NeuN, MBP, CD31), and axon survival (5-HT, NF, RFP).
  • Western Blotting: To quantify the expression of pro-inflammatory, anti-inflammatory, and apoptotic markers.
  • Behavioral Assessments: Including the Basso, Beattie, and Bresnahan (BBB) locomotor rating scale, detailed hindlimb kinematic analysis, and electromyography (EMG) to evaluate functional recovery and muscle control.
  • Electrophysiology: Somatosensory evoked potentials (SSEPs) were measured to assess the functional integrity of sensory pathways.
  • EV Tracking: CM-Dil labeled EVs were used to visualize their distribution in the injured spinal cord.

Datasets

Not explicitly discussed as "datasets" in the traditional machine learning sense. The study relies on data collected from animal experiments. The primary "dataset" is the collection of histological images, protein expression levels, behavioral scores, and electrophysiological recordings from rats subjected to different treatment conditions.

Key Insights and Ideas

  • Porous GelMA is Crucial for Sustained EV Release: The engineered porous structure of the GelMA hydrogel significantly enhances the release of MSC-EVs compared to non-porous hydrogels. This is attributed to increased permeability.
  • MN-MSC Patch Provides Long-Term EV Supply: By embedding live MSCs, the patch acts as a continuous factory for EVs, ensuring a sustained therapeutic presence at the injury site for at least 7 days, which is critical for addressing the chronic inflammatory environment post-SCI.
  • Localized Delivery Minimizes Damage: Applying the patch topically beneath the dura mater avoids direct invasion of the spinal cord tissue, minimizing iatrogenic damage and potential side effects associated with direct transplantation.
  • Sustained EV Delivery Drives Functional Recovery: The combination of sustained EV delivery and localized application by the MN-MSC patch leads to remarkable improvements in hindlimb motor function, muscle control, and overall locomotor recovery, far exceeding other treatment groups.
  • MNs Enhance Therapeutic Efficacy: While MSCs and EVs alone show some benefit, the microneedle platform is essential for effective delivery and sustained action, highlighting the synergy between the delivery system and the therapeutic payload.

Key Results

  • Reduced Inflammation and Scarring: The MN-MSC patch treatment significantly reduced pro-inflammatory markers (TNF-α, IL-1β, iNOS, MMP-9) and increased anti-inflammatory markers (TGF-β, Arg-2) in the injured spinal cord tissue. It also reduced cavity and scar tissue formation.
  • Axon Protection and Regeneration: Treatment with the MN-MSC patch led to increased survival of spared axons below the lesion site and even suggested potential for regrowth into the lesion area, as evidenced by 5-HT, NF, and RFP staining.
  • Improved Locomotor Function: Rats treated with the MN-MSC patch showed significantly higher BBB scores, improved hindlimb kinematics (stride length, body weight support, joint angles), and better muscle control (EMG signals) compared to control groups. Some rats even achieved sustained weight support and plantar stepping.
  • EV Localization: CM-Dil labeled EVs were successfully localized to the spinal cord injury site after MN-EV patch implantation, confirming localized delivery.
  • MSC Viability: MSCs within the MN-MSC patch remained viable for at least 7 days post-implantation, ensuring continued EV production.

Limitations and Future Work

  • Optimal Implantation Timing: While effective within the first week post-SCI, the precise optimal window for MN-MSC patch implantation requires further investigation.
  • EV Release Kinetics: The exact relationship between the total number of EVs released and therapeutic efficacy needs further study.
  • Degradation of MN Patch: The long-term degradation profile of the GelMA hydrogel needs to be fully characterized.
  • MSC Stemness Preservation: Strategies to better preserve the stemness of transplanted MSCs could further improve treatment efficacy.
  • Micro/Nano-Scale MN Structures: The authors plan to develop more precise porous MN structures using two-photon 3D printing for enhanced control over pore size and EV release.
  • Artificial Dura: The current MN-MSC patch may not be suitable as an artificial dura, and a more robust scaffold structure is being developed.
  • Contribution of Other Factors: While EVs are highlighted, the potential synergistic contribution of other soluble factors released by MSCs cannot be entirely ruled out.

Summary updated

Abstract

The transplantation of mesenchymal stem cells-derived secretome, particularly extracellular vesicles is a promising therapy to suppress spinal cord injury-triggered neuroinflammation. However, efficient delivery of extracellular vesicles to the injured spinal cord, with minimal damage, remains a challenge. Here we present a device for the delivery of extracellular vesicles to treat spinal cord injury. We show that the device incorporating mesenchymal stem cells and porous microneedles enables the delivery of extracellular vesicles. We demonstrate that topical application to the spinal cord lesion beneath the spinal dura, does not damage the lesion. We evaluate the efficacy of our device in a contusive spinal cord injury model and find that it reduces the cavity and scar tissue formation, promotes angiogenesis, and improves survival of nearby tissues and axons. Importantly, the sustained delivery of extracellular vesicles for at least 7 days results in significant functional recovery. Thus, our device provides an efficient and sustained extracellular vesicles delivery platform for spinal cord injury treatment.
BibTeX
@inproceedings{fang2023porous,
  author = {Ao Fang and Yifan Wang and Naiyu Guan and Yanming Zuo and Lingmin Lin and Binjie Guo and Aisheng Mo and Yile Wu and Xurong Lin and Wanxiong Cai and Xiangfeng Chen and Jingjia Ye and Zeinab Abdelrahman and Xiaodan Li and Hanyu Zheng and Zhonghan Wu and Shuang Jin and Kan Xu and Yan Huang and Xiaosong Gu and Bin Yu and Xuhua Wang},
  title = {{Porous microneedle patch with sustained delivery of extracellular vesicles mitigates severe spinal cord injury}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-023-39745-2},
}
Figure